Published in Milbank Q on December 01, 2008
Will cardiovascular disease prevention widen health inequalities? PLoS Med (2010) 2.89
Practical use of the Framingham risk score in primary prevention: Canadian perspective. Can Fam Physician (2011) 2.27
Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med (2010) 2.06
Addressing population health and health inequalities: the role of fundamental causes. Am J Public Health (2014) 1.07
Impact on social inequalities of population strategies of prevention for folate intake in women of childbearing age. Am J Public Health (2011) 0.91
Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged? Can J Hosp Pharm (2014) 0.89
HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections. Sex Transm Dis (2016) 0.89
Sleep duration and its association with ambulatory blood pressure in a school-based, diverse sample of adolescents. Am J Hypertens (2014) 0.80
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 0.77
The Devil Is in the Details: Achieving Reductions in Global Cardiovascular Disease Mortality. Circ Cardiovasc Qual Outcomes (2015) 0.75
Cardiac risk is not associated with hypertension treatment intensification. Am J Manag Care (2012) 0.75
Modeling Individual Patient Preferences for Colorectal Cancer Screening Based on Their Tolerance for Complications Risk. Med Decis Making (2016) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Sick individuals and sick populations. Int J Epidemiol (1985) 23.44
Cardiovascular disease risk profiles. Am Heart J (1991) 21.65
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 9.18
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet (1992) 7.04
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q (2004) 3.60
Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J (2003) 3.55
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J (2003) 3.48
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ (2000) 3.30
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA (1995) 3.21
Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet (1999) 3.05
Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J (2004) 2.91
Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med (2004) 2.84
INTERSALT study findings. Public health and medical care implications. Hypertension (1989) 2.69
Comparison of an aggressive (U.S.) and a less aggressive (Canadian) policy for cholesterol screening and treatment. Ann Intern Med (1991) 2.61
Revisiting Rose: strategies for reducing coronary heart disease. BMJ (2006) 2.53
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52
Evaluation of acute physiology and chronic health evaluation III predictions of hospital mortality in an independent database. Crit Care Med (1998) 2.44
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol (2006) 2.27
Operative mortality in colorectal cancer: prospective national study. BMJ (2003) 1.89
Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol (2005) 1.88
Projected effects of high-risk versus population-based prevention strategies in coronary heart disease. Am J Epidemiol (1985) 1.84
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord (1998) 1.75
Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) (2005) 1.57
Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation (2001) 1.55
Adjustment for regression dilution in epidemiological regression analyses. Ann Epidemiol (1998) 1.43
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA (1991) 1.42
Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology (1999) 1.30
Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res (2005) 1.27
Prediction of survival for older hospitalized patients: the HELP survival model. Hospitalized Elderly Longitudinal Project. J Am Geriatr Soc (2000) 1.24
Strategies of prevention revisited: effects of imprecise measurement of risk factors on the evaluation of "high-risk" and "population-based" approaches to prevention of cardiovascular disease. J Clin Epidemiol (1991) 1.10
Physical activity and mortality across cardiovascular disease risk groups. Med Sci Sports Exerc (2004) 1.07
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol (1998) 1.05
Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation (2001) 1.03
Functional status versus utilities in survivors of myocardial infarction. Med Care (1991) 0.95
Predicting patient outcome from acute renal failure comparing three general severity of illness scoring systems. Kidney Int (2000) 0.93
Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes. JAMA (1998) 0.93
Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med (1998) 0.86
Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks. Anticancer Res (2000) 0.84
Using the receiver operating characteristic curve to select pretreatment and pathologic predictors for early and late postprostatectomy PSA failure. Urology (2001) 0.81
Prospectively validated prediction of organ failure and hypotension in patients with septic shock: the Systemic Mediator Associated Response Test (SMART). Shock (2000) 0.80
Effectiveness of coronary heart disease risk management in high-risk patients. Clin Cardiol (1994) 0.77
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med (2004) 6.86
Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study. Lancet (2012) 6.60
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
The value of medical spending in the United States, 1960-2000. N Engl J Med (2006) 5.38
Diabetes control with reciprocal peer support versus nurse care management: a randomized trial. Ann Intern Med (2010) 5.18
The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. J Gen Intern Med (2002) 4.79
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med (2012) 4.51
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med (2003) 3.81
Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med (2012) 3.79
Lessons from the mammography wars. N Engl J Med (2010) 3.68
An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: sensitivity and specificity analysis. Proteomics (2005) 3.51
Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med (2006) 3.50
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics (2011) 3.37
The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med (2003) 3.32
The relationship between knowledge of recent HbA1c values and diabetes care understanding and self-management. Diabetes Care (2005) 3.11
Are bad outcomes from questionable clinical decisions preventable medical errors? A case of cascade iatrogenesis. Ann Intern Med (2002) 3.07
Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med (2007) 3.05
Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med (2007) 3.03
The economic burden of major adult visual disorders in the United States. Arch Ophthalmol (2006) 2.92
Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care (2003) 2.88
Patients, privacy and trust: patients' willingness to allow researchers to access their medical records. Soc Sci Med (2006) 2.86
Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care (2003) 2.85
Medicine needs evolution. Science (2006) 2.83
Accepting critically ill transfer patients: adverse effect on a referral center's outcome and benchmark measures. Ann Intern Med (2003) 2.75
Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med (2004) 2.73
Whom should we profile? Examining diabetes care practice variation among primary care providers, provider groups, and health care facilities. Health Serv Res (2002) 2.68
Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol (2006) 2.66
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? J Gen Intern Med (2003) 2.51
Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation (2008) 2.45
Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res (2006) 2.43
Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med (2010) 2.41
Case management for patients with poorly controlled diabetes: a randomized trial. Am J Med (2004) 2.41
The human proteome project: current state and future direction. Mol Cell Proteomics (2011) 2.34
Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med (2005) 2.32
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol (2006) 2.27
The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst (2004) 2.26
Predictors of physician career satisfaction, work-life balance, and burnout. Obstet Gynecol (2007) 2.25
An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ (2010) 2.22
Uninsured adults presenting to US emergency departments: assumptions vs data. JAMA (2008) 2.15
The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. Nat Biotechnol (2012) 2.14
ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics (2009) 2.11
Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med (2010) 2.06
Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Med Care (2010) 2.05
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
In the clinic. Type 2 diabetes. Ann Intern Med (2015) 2.00
Novel gene and gene model detection using a whole genome open reading frame analysis in proteomics. Genome Biol (2006) 1.98
Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology (2008) 1.95
Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med (2011) 1.92
Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation (2013) 1.89
How well do patients' assessments of their diabetes self-management correlate with actual glycemic control and receipt of recommended diabetes services? Diabetes Care (2003) 1.81
Does physician communication influence older patients' diabetes self-management and glycemic control? Results from the Health and Retirement Study (HRS). J Gerontol A Biol Sci Med Sci (2007) 1.80
Performance measurement in search of a path. N Engl J Med (2007) 1.78
Metrics for the Human Proteome Project 2013-2014 and strategies for finding missing proteins. J Proteome Res (2013) 1.76
The impact of diabetes on workforce participation: results from a national household sample. Health Serv Res (2004) 1.70
Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics (2011) 1.69
Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation (2007) 1.68
Specialty care and the patient-centered medical home. Med Care (2011) 1.68
Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One (2009) 1.68
Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care (2005) 1.64
Meeting report: hazard assessment for nanoparticles--report from an interdisciplinary workshop. Environ Health Perspect (2007) 1.64
What causes pregnancy loss? Preexisting mental illness as an independent risk factor. Gen Hosp Psychiatry (2007) 1.63
Metscape: a Cytoscape plug-in for visualizing and interpreting metabolomic data in the context of human metabolic networks. Bioinformatics (2010) 1.62
All-or-nothing treatment targets make bad performance measures. Am J Manag Care (2007) 1.61
Marriage and cohabitation outcomes after pregnancy loss. Pediatrics (2010) 1.61
New diabetes HEDIS blood pressure quality measure: potential for overtreatment. Am J Manag Care (2010) 1.60
Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics (2005) 1.59
Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) (2005) 1.57
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol (2008) 1.55
When there is too much to do: how practicing physicians prioritize among recommended interventions. J Gen Intern Med (2004) 1.53
State of the human proteome in 2013 as viewed through PeptideAtlas: comparing the kidney, urine, and plasma proteomes for the biology- and disease-driven Human Proteome Project. J Proteome Res (2013) 1.52
Open-access electronic case report journals: the rationale for case report guidelines. J Clin Epidemiol (2013) 1.51
Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). Cancer Epidemiol Biomarkers Prev (2003) 1.51
Systematic comparison of the human saliva and plasma proteomes. Proteomics Clin Appl (2009) 1.51
Impact of patient risk on the hospital volume-outcome relationship in coronary artery bypass grafting. Arch Intern Med (2005) 1.48
Comparing clinical automated, medical record, and hybrid data sources for diabetes quality measures. Jt Comm J Qual Improv (2002) 1.48
Depression among older adults in the United States and England. Am J Geriatr Psychiatry (2010) 1.48
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol (2009) 1.47
Evolution in health and medicine Sackler colloquium: Making evolutionary biology a basic science for medicine. Proc Natl Acad Sci U S A (2009) 1.45
Shifting views on lipid lowering therapy. BMJ (2010) 1.44
Identification of novel alternative splice isoforms of circulating proteins in a mouse model of human pancreatic cancer. Cancer Res (2009) 1.40
Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics (2005) 1.38
Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med (2012) 1.38
Data management and preliminary data analysis in the pilot phase of the HUPO Plasma Proteome Project. Proteomics (2005) 1.37
A first step toward completion of a genome-wide characterization of the human proteome. J Proteome Res (2012) 1.36
The biology/disease-driven human proteome project (B/D-HPP): enabling protein research for the life sciences community. J Proteome Res (2012) 1.35
Interhospital transfers among Medicare beneficiaries admitted for acute myocardial infarction at nonrevascularization hospitals. Circ Cardiovasc Qual Outcomes (2010) 1.31
Temporal quantitative proteomics by iTRAQ 2D-LC-MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-beta-Induced epithelial-mesenchymal transition. J Proteome Res (2009) 1.29
Patient-centered performance management: enhancing value for patients and health care systems. JAMA (2013) 1.29